RINVOQ Abbvie Pty Ltd
Product name
RINVOQ
Sponsor
Accepted date
Apr-2026
Active ingredients
upadacitinib hemihydrate
Summary of proposed indication
RINVOQ (upadacitinib hemihydrate) is proposed as a treatment for adults and adolescents 12 years of age and older with severe alopecia areata. Alopecia areata is a condition where the body's immune system mistakenly attacks hair roots, which can cause hair loss.
Application type
C (new indication)
Publication date
Apr-2026